ABCELLERA BIOLOGICS INC (ABCL)       10.97  -0.21 (-1.88%)

10.97  -0.21 (-1.88%)

CA00288U1066 - Common Stock - After market: 10.96 -0.01 (-0.09%)

ABCELLERA BIOLOGICS INC10.97

NASDAQ:ABCL (2/6/2023, 7:00:00 PM)-0.21 (-1.88%)

After market: 10.96 -0.01 (-0.09%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS Sector Health Care
GICS Industry Life Sciences Tools & Services

Chartmill FA Rating
Valuation Growth
Profitability Health
Dividend

Overview
Earnings (Last) 11-08 2022-11-08/amc Earnings (Next) 02-21 2023-02-21/amc
Ins Owners 20.37% Inst Owners 48.58%
Market Cap 3.14B Shares 286.10M
PE 13.89 Fwd PE N/A
Dividend Yield N/A Analysts 83.75
IPO 12-11 2020-12-11

Stock Screener Links

Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ABCL Daily chart

Company Profile

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. The company is headquartered in Vancouver, British Columbia and currently employs 386 full-time employees. The company went IPO on 2020-12-11. The Company’s full-stack, AI-powered antibody discovery platform searches and analyzes the database of natural immune systems to find antibodies that can be developed as drugs. The company rebuilds the platform that integrates modern technologies from engineering, microfluidics, single-cell analysis, high-throughput genomics, machine learning, and hyper-scale data science. The firm partners with drug developers of all sizes, from large cap pharmaceutical to small biotechnology companies, enabling them to tackle the toughest problems in drug development.

Company Info

ABCELLERA BIOLOGICS INC

2215 Yukon Street

Vancouver BRITISH COLUMBIA

P: 16045599005.0

Employees: 386

Website: https://www.abcellera.com/

ABCL News

News Image5 days ago - InvestorPlaceThe 7 Most Undervalued Biotech Stocks to Buy in February 2023

Get your hands on the latest medical innovations at a compelling discount with the most undervalued biotech stocks to buy.

News Image5 days ago - Seeking AlphaLLY stock slips as falling demand for COVID therapy hurts topline (NYSE:LLY)

Eli Lilly (LLY) fell in the pre-market Thursday after reporting lower than expected revenue for Q4 2022 as demand for its COVID-19 therapy continued to plunge. Read the full story here.

News Image5 days ago - AbCellera Biologics Inc.AbCellera to Present at the SVB Securities Global Biopharma Conference on February 15, 2023News Image13 days ago - AbCellera Biologics Inc.AbCellera to Report Full Year 2022 Financial Results on February 21, 2023News Image18 days ago - AbCellera Biologics Inc.AbCellera Announces that the U.S. Patent Trial and Appeal Board Upholds Microfluidic Cell Culture PatentNews Image25 days ago - Market News VideoAbCellera Biologics (ABCL) Shares Cross Above 200 DMA

ABCL Twits

Here you can normally see the latest stock twits on ABCL, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example